Market Place
Sourcing Support
Gilead Sciences Announces First Quarter 2024 Financial Results
26 Apr 2024 //
PRESS RELEASE
FDA Expands Indication for Gilead`s Vemlidy to Treat Chronic HBV Infection
28 Mar 2024 //
BUSINESSWIRE
ViiV, Gilead row escalates to feds after self-regulation fails
02 May 2023 //
FIERCE PHARMA
Lupin receives approval from USFDA for Tenofovir Alafenamide tablets
01 Apr 2023 //
FREE PRESS JOURNAL
Lupin`s Generic Tenofovir Alafenamide Receives Approval in the U.S.
30 Mar 2023 //
FDA
Lupin gets USFDA nod for Dolutegravir, Emtricitabine and Tenofovir tablets
31 Jan 2023 //
ECONOMIC TIMES
Gilead receives EC marketing authorisation for HIV treatment in children
30 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
Gilead`s Vemlidy enters the pediatric hepatitis B arena with FDA green light
03 Nov 2022 //
FIERCEPHARMA
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy
24 Oct 2022 //
BUSINESSWIRE
My Biggest Worry About Gilead Sciences
14 Sep 2022 //
FOOL
Gilead trumpets a Biktarvy win in HIV, hepatitis B co-infection
02 Aug 2022 //
FIERCEPHARMA
Lupin gets USFDA nod to market drug used to treat chronic hepatitis B
18 Apr 2022 //
ECONOMIC TIMES
FDA Approves Expanded Indication of Gilead’s Biktarvy for HIV-1 in Pediatrics
18 Oct 2021 //
BUSINESSWIRE
Gilead Canada Announces Notice of Compliance for DESCOVY®
01 Dec 2020 //
BUSINESSWIRE
Gilead to present antiretroviral therapies at virtual APACC 2020 conference
09 Oct 2020 //
BIOSPECTRUMASIA
UK marketing police slam Gilead for misleading Biktarvy promos
15 Jul 2020 //
FIERCE PHARMA
NPPA seeks clarification on Gilead`s drug pricing plea
31 Jan 2020 //
ECONOMICTIMES
DoP rejects Emcure Pharma`s review application against NPPA`s price
23 Jan 2020 //
PHARMABIZ
A USPTO legal adviser off controversial Gilead HIV case after activists allege
13 Dec 2019 //
ENDPTS
Gilead’s converting Truvada PrEP users to Descovy faster than expected
03 Dec 2019 //
FIERCE PHARMA
Vemlidy tackles hep B in late-stage trials
14 Nov 2019 //
PHARMA TIMES
US Sues Gilead Over HIV Drug Patents
08 Nov 2019 //
RAPS
Gilead touts new data for fast-growing Biktarvy as older HIV meds show some cracks
07 Nov 2019 //
BUSINESSWIRE
China NMPA approves Biktarvy to treat HIV-1 Infection
16 Aug 2019 //
BIOSPECTRUMASIA
GSK`s Dovato meets primary goal in late-stage HIV study
09 Jul 2019 //
REUTERS
FDA Unveils 34 New and Revised Product-Specific Draft Guidances
17 May 2019 //
RAPS
J&J-backed AIDS film picked up by Verizon Media
10 May 2019 //
FIERCE PHARMA
Singapore HSA Approves Biktarvy for Treatment of HIV-1 Infection
13 Feb 2019 //
PR NEWSWIRE
Gilead`s Vemlidy receives Chinese approval for chronic HBV infection
20 Nov 2018 //
PHARMABIZ
China NMPA Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic HBV
15 Nov 2018 //
PR NEWSWIRE
AIDS Foundation Petitions Supreme Court to Invalidate Gilead HIV Drug Patents
20 Aug 2018 //
RAPS
European Commission Grants Marketing Authorization for Gilead’s Biktarvy®
23 Jun 2018 //
PRESS RELEASE
Gilead strikes back at GSK with +ve HIV head-to-head trial data for blockbuster
07 Mar 2018 //
FIERCE PHARMA
Gilead says switching studies back new HIV therapy Biktarvy
06 Mar 2018 //
PMLIVE
ContraVir`s Announces TXL™ Has Been Granted Orphan Drug Designation
22 Feb 2018 //
PRESS RELEASE
US green light for Gilead’s HIV combo
08 Feb 2018 //
PHRMA TIMES
Sanofi`s diabetes sales hit hard by PBM formulary moves
07 Feb 2018 //
FIERCE PHARMA
Gilead gets a blockbuster boost from an FDA OK of HIV triplet Biktarvy
07 Feb 2018 //
ENDPTS
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
06 Jan 2018 //
FIERCE PHARMA
Mylan wants to capture chronic Hep B market
08 Dec 2017 //
ECONOMIC TIMES
Janssen’s New Darunavir-Based Single Tablet Regimen SYMTUZA
25 Oct 2017 //
BUSINESSWIRE
Janssen-Cilag International Generic Symtuza Receives Approval In Europe
27 Sep 2017 //
EMA
EC approves Janssen’s Symtuza
26 Sep 2017 //
PHARMA TIMES
FDA Accepts Supplemental NDA for Eisai`s Lenvatinib for Treatment Liver Cancer
26 Sep 2017 //
PR NEWSWIRE
Gilead`s HIV Triple Combo Gets Sped-up FDA Review, Decision Date Locked Down
12 Aug 2017 //
BIOSPACE
FDA Grants Priority Review to Gilead`s Fixed-Dose BIC/FTC/TAF HIV Treatment
11 Aug 2017 //
DDDMAG
Gilead Submits New Drug Application to U.S. Food & Drug Administration
12 Jun 2017 //
BUSINESSWIRE
Gilead’s HIV drug ‘non-inferior’ to ViiV’s Tivicay
31 May 2017 //
PHARMATIMES
Gilead Sciences Gets EU Nod For Vemlidy
10 Mar 2017 //
EMA
Gilead’s genvoya shows significantly higher rates of virologic suppression
15 Feb 2017 //
PHARMABIZ
Value investors pile into Gilead expecting strong long-term growth: report
07 Feb 2017 //
FIERCE PHARMA
EU Approves Gilead’s Hepatitis B Therapy Vemlidy
13 Jan 2017 //
PHARMATIMES
The Glaxo-Gilead HIV Battle Could Be Epic
28 Dec 2016 //
SEEKING ALPHA
Gilad Sciences receives Japanese nod for Vemlidy
21 Dec 2016 //
PHARMABIZ
